BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1425740)

  • 1. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of anaerobic bacteria to PD 131628.
    Nord CE; Hagelbäck A
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Oct; 12(10):784-6. PubMed ID: 7802861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
    Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of anaerobic bacteria to Sch 34343 and other antibiotics.
    Glupczynski Y; Gordts B; van der Linden MP; Labbé M; Yourassowsky E; Butzler JP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():193-8. PubMed ID: 4030548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.
    Rylander M; Nord CE; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):919-24. PubMed ID: 2512142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM; Finegold SM
    Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of HMR 3647 against anaerobic bacteria.
    Edlund C; Sillerström E; Wahlund E; Nord CE
    J Chemother; 1998 Aug; 10(4):280-4. PubMed ID: 9720465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L; Devos J; Romond C
    Int J Clin Pharmacol Res; 1987; 7(1):39-43. PubMed ID: 3473047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of Sch 34343 and other antimicrobial agents against anaerobic bacteria.
    Nord CE; Olsson-Liljequist B
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():183-8. PubMed ID: 2863246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.